abt-199 and embelin

abt-199 has been researched along with embelin* in 1 studies

Other Studies

1 other study(ies) available for abt-199 and embelin

ArticleYear
Embelin potentiates venetoclax-induced apoptosis in acute myeloid leukemia cells.
    Toxicology in vitro : an international journal published in association with BIBRA, 2021, Volume: 76

    Acute myeloid leukemia (AML) belongs to a group of hematological cancer whose relapse cases are often associated with chemoresistance that impairs treatment success and contributes to a poor outcome. For this reason, there is an urgent need for the development of new therapeutic strategies. Herein, we explore the combination of venetoclax, a BCL2 inhibitor, and embelin, an XIAP inhibitor, in the AML cell lines. Combinatory treatment of venetoclax and embelin potentiated cytotoxic effects of these drugs, demonstrating that both in combination present lower IC

    Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Survival; DNA Damage; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; X-Linked Inhibitor of Apoptosis Protein

2021